Nachrichten zur Eisai Co. Ltd. Aktie

The FDAs Next Call on an Alzheimers Drug Is Due This Week

Biogen and Eisai are jointly developing lecanemab. A decision on accelerated approval is expected by Friday....…

Biogen/ Eisai deserve $30K price tag for new Alzheimer’s drug – Wells Fargo

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

New Alzheimers Drug Could Be Priced Up to $20,000 a Year: Group

The FDA next month will consider approving the drug Lecanemab from Biogen and Eisai....…

EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

TOKYO and CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen…

Astellas Pharma, Eisai, Daiichi Sankyo and Takeda join hands to reduce environmental burden in the field of pharmaceutical packaging

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

TOKYO and OSAKA, Japan, Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas"),…

Catalyst Pharma gains U.S. rights to Eisai epilepsy drug Fycompa

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

Acquisition Expands The Companys Commercial Portfolio With An Established U.S. Marketed Product...…

EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES

TOKYO, Dec. 14, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and…

Biogen, Eisai prompt Medicare to reevaluate Alzheimer’s coverage after new data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

NUTLEY, N.J., Dec. 1, 2022 /PRNewswire/ -- Eisai announced today that new study results on its in-house discovered and developed…

5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners

Results of clinical trial point to a stable future for Eisai and Biogen's lecanemab once the therapy is approved by…

Biogens Alzheimer-Mittel bremst geistigen Abbau – Längere Studien nötig

Forscher haben neue Studiendaten zum grossen Hoffnungsträger der US-Firma Biogen und des japanischen Partners Eisai in Kampf gegen Alzheimer veröffentlicht....…

Biogen and Eisai Strengthen Lead in Alzheimer’s Drug Race. The Stocks Are Rising.

Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab....…

Biogen: Frische Daten zum Alzheimer-Hoffnungsträger Lecanemab vorgelegt - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Biogen-Aktienanalyse von "Der Aktionär": Laut Michel Doepke vom Anlegermagazin "Der Aktionär" bleibt die Biogen-Aktie (ISIN: US09062X1037, WKN: 789617,…

Biogen: Weitere Alzheimer-Daten sorgen für Furore

Biogen und der Entwicklungspartner Eisai haben auf dem CTAD Alzheimer Congress in San Francisco frische Daten zu ihrem Alzheimer-Hoffnungsträger Lecanemab…

Starke Nebenwirkungen: Längere Studien zu Biogens Alzheimer-Mittel empfohlen

NEW YORK (dpa-AFX) - Forscher haben neue Studiendaten zum großen Hoffnungsträger der US-Firma Biogen und des japanischen Partners Eisai in…

Biogen, Eisais Alzheimers Data Confirm Benefit, But Questions Loom

Japan's Eisai, which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the…

Eisai, Biogen Hit By 2nd Death Related To Alzheimer Trial Drug

WESTON (dpa-AFX) - Concerns are increasing over the safety of Eisai and Biogens (BIIB) Alzheimers disease drug lecanemab. Ahead of…

Its Crunch Time for Biogen Stock. Data on Alzheimers Trial Are Due Tonight.

Japan's Eisai , which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that…

Eisai Shares Fall Following Report of Patient Death in Alzheimers Trial

Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial...…

EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

EMBARGOED UNTIL DECEMBER 2, 2022 NUTLEY, N.J., Nov. 23, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Morphosys: Aktie nach Alzheimer-Flop bei Roche auf Talfahrt

Im milliardenschweren Rennen um ein wirksames Alzheimer-Medikament hat der Morphosys-Partner Roche einen heftigen Rückschlag erlitten. Die Morphosys-Papiere brechen um knapp…

Corporate News: DKSH Management AG

DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of two Brands From Eisai...…

Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA

The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase…

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022…

Morphosys: Termin vormerken!

Das Forschungsduo Biogen und Eisai hat vor Kurzem mit positiven Studiendaten zu einem Alzheimer-Medikament für Furore gesorgt. Auch andere Biotech-Unternehmen…

Alzheimer-Aktien: Weg aus dem Wirrwarr

Biogen und der japanische Partner Eisai können einen Forschungserfolg gegen Alzheimer vermelden....…

dpa-AFX ProFeed